Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Cwm LLC

Cwm LLC increased its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 93.7% during the 3rd quarter, Holdings Channel reports. The fund owned 34,167 shares of the company’s stock after purchasing an additional 16,530 shares during the quarter. Cwm LLC’s holdings in Xeris Biopharma were worth $97,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC raised its position in Xeris Biopharma by 188.5% in the 3rd quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock valued at $172,000 after purchasing an additional 39,335 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Xeris Biopharma during the 2nd quarter worth approximately $75,000. The Manufacturers Life Insurance Company increased its position in shares of Xeris Biopharma by 10.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,805 shares of the company’s stock valued at $130,000 after purchasing an additional 5,291 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Xeris Biopharma by 4.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock valued at $2,684,000 after purchasing an additional 52,074 shares in the last quarter. Finally, Asset Management Group Inc. lifted its position in shares of Xeris Biopharma by 130.7% during the 2nd quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock worth $60,000 after purchasing an additional 15,000 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Down 1.2 %

Shares of XERS opened at $3.20 on Friday. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.46 and a 52-week high of $3.39. The stock has a 50 day moving average price of $2.87 and a 200 day moving average price of $2.39. The company has a market capitalization of $474.42 million, a price-to-earnings ratio of -6.81 and a beta of 2.76.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The firm had revenue of $48.07 million for the quarter, compared to the consensus estimate of $46.80 million. During the same period last year, the firm posted ($0.14) EPS. On average, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.